Compare · ESTA vs INMD
ESTA vs INMD
Side-by-side comparison of Establishment Labs Holdings Inc. (ESTA) and InMode Ltd. (INMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. ESTA focuses on Industrial Specialties, while INMD focuses on Biotechnology: Electromedical & Electrotherapeutic Apparatus.
- ESTA is the larger of the two at $2.11B, about 2.8x INMD ($762.8M).
- ESTA has been more active in the news (4 items in the past 4 weeks vs 3 for INMD).
- INMD has more recent analyst coverage (20 ratings vs 15 for ESTA).
- Company
- Establishment Labs Holdings Inc.
- InMode Ltd.
- Price
- -
- -
- Market cap
- $2.11B
- $762.8M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Industrial Specialties
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2019
- News (4w)
- 4
- 3
- Recent ratings
- 15
- 20
Establishment Labs Holdings Inc.
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand. It also provides Divina 3D surgical simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution. The company sells its products through exclusive distributors and direct sales force in Europe, Latin America, the Asia-Pacific, and internationally. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.
InMode Ltd.
InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies. The company offers minimally-invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. InMode Ltd. offers its products directly in United States, Canada, United Kingdom, Spain, India, Australia, and France, as well as through distributors in 47 countries. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel.
Latest ESTA
- Amendment: SEC Form SCHEDULE 13G/A filed by Establishment Labs Holdings Inc.
- SEC Form 10-Q filed by Establishment Labs Holdings Inc.
- SEC Form 8-K filed by Establishment Labs Holdings Inc.
- Establishment Labs® Reports Third Quarter 2026 Financial Results
- Establishment Labs® to Announce Third Quarter 2026 Financial Results on October 29
- Stifel initiated coverage on Establishment Labs with a new price target
- SEC Form 8-K filed by Establishment Labs Holdings Inc.
- Establishment Labs® Receives FDA Approval for Additional Sizes of Motiva Implants®
- Director Gillin Leslie was granted 262 shares, increasing direct ownership by 1% to 18,856 units (SEC Form 4)
- Director Schutter Edward J was granted 253 shares, increasing direct ownership by 0.14% to 178,205 units (SEC Form 4)
Latest INMD
- SEC Form 6-K filed by InMode Ltd.
- InMode Reports Third Quarter 2026 Financial Results: Quarterly GAAP Revenues of $92.1 Million; Reaffirms Full-Year 2026 Financial Outlook
- SEC Form 6-K filed by InMode Ltd.
- Steel Partners Holdings L.P. Issues Open Letter to All InMode Stakeholders and Sets October 30, 2026 Expiration for Its $16.75 Per Share All-Cash Offer
- InMode to Report Third Quarter 2026 Financial Results on November 11, 2026, Expects Third Quarter Revenue of $91.8 Million to $92.0 Million, Reiterates FY 2026 Revenue Guidance Between $365M-$375M
- SEC Form 6-K filed by InMode Ltd.
- InMode Advances RF Microneedling Comfort with the Launch of Morpheus8 Cool
- SEC Form 6-K filed by InMode Ltd.
- Chief Financial Officer Itzkovich Moshe was granted 14,000 units of Ordinary Shares, increasing direct ownership by 57% to 38,430 units (SEC Form 4)
- SEC Form 6-K filed by InMode Ltd.